Ionis Pharmaceuticals (NASDAQ:IONS) Issues Earnings Results

Ionis Pharmaceuticals (NASDAQ:IONS) released its quarterly earnings data on Wednesday. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.29, FiscalAI reports. The firm had revenue of $246.00 million during the quarter, compared to the consensus estimate of $197.45 million. Ionis Pharmaceuticals had a negative net margin of 40.36% and a negative return on equity of 68.82%. The firm’s revenue was up 86.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.93) earnings per share.

Here are the key takeaways from Ionis Pharmaceuticals’ conference call:

• TRYNGOLZA launch momentum accelerated in Q1 with growing demand, broadening prescriber mix and initial European rollout with partner Sobi, contributing to $27M in product sales for the quarter.
• Olezarsen (branded TRYNGOLZA) received FDA priority review with a PDUFA of June 30, a new annual WAC of $40,000, and management raised peak U.S. sales expectations to greater than $3 billion based on HCP and payer research.
• Zilganersen’s NDA for Alexander disease was accepted with a PDUFA of September 22, the expanded access program is underway, and the company targets this as its first independent neurology launch.
• Strong Q1 financials: total revenue of $246M (up 87% YoY), cash of ~$1.9B, and raised 2026 revenue guidance to $875M–$900M with product-level guidance for TRYNGOLZA ($100M–$110M) and DAWNZERA ($110M–$120M), plus an improved non?GAAP operating loss outlook.
• Management expects a significant second-quarter decline in TRYNGOLZA revenue driven by the April 1 price reset to $40,000 before a steady return to growth post-approval for the sHTG indication.

Ionis Pharmaceuticals Stock Performance

Shares of IONS traded up $2.41 during midday trading on Wednesday, hitting $74.19. 2,155,107 shares of the stock traded hands, compared to its average volume of 2,175,611. Ionis Pharmaceuticals has a 1-year low of $29.85 and a 1-year high of $86.74. The firm has a market capitalization of $12.25 billion, a PE ratio of -30.39 and a beta of 0.40. The company has a debt-to-equity ratio of 2.76, a quick ratio of 3.81 and a current ratio of 3.83. The business’s 50 day moving average price is $75.61 and its two-hundred day moving average price is $77.30.

Insider Buying and Selling at Ionis Pharmaceuticals

In related news, EVP Kyle Jenne sold 4,902 shares of Ionis Pharmaceuticals stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $75.17, for a total transaction of $368,483.34. Following the sale, the executive vice president directly owned 23,713 shares in the company, valued at $1,782,506.21. The trade was a 17.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director B Lynne Parshall sold 5,000 shares of Ionis Pharmaceuticals stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $76.27, for a total transaction of $381,350.00. Following the sale, the director owned 51,344 shares in the company, valued at approximately $3,916,006.88. This represents a 8.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 864,155 shares of company stock valued at $67,020,422. 2.71% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ionis Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of IONS. Brown Brothers Harriman & Co. bought a new stake in shares of Ionis Pharmaceuticals during the fourth quarter valued at about $27,000. Quarry LP bought a new stake in shares of Ionis Pharmaceuticals during the third quarter valued at about $38,000. Johnson Financial Group Inc. bought a new stake in shares of Ionis Pharmaceuticals during the third quarter valued at about $44,000. Los Angeles Capital Management LLC bought a new stake in shares of Ionis Pharmaceuticals during the fourth quarter valued at about $52,000. Finally, Summit Securities Group LLC bought a new stake in shares of Ionis Pharmaceuticals during the fourth quarter valued at about $59,000. 93.86% of the stock is currently owned by institutional investors.

Key Stories Impacting Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Q1 results beat estimates — Ionis reported Q1 revenue of $246M (up ~86% YoY) and an EPS loss smaller than consensus, giving the quarter a clear beat on top and bottom lines. Read More.
• Positive Sentiment: Raised FY?2026 revenue guidance — management issued revenue guidance of $875M–$900M, well above the prior consensus (~$816M), implying stronger expected commercial performance for the year. Read More.
• Positive Sentiment: Regulatory catalyst from partner GSK — GSK’s NDA for bepirovirsen (Ionis?discovered ASO for chronic hepatitis B) was accepted for Priority Review and granted Breakthrough Therapy designation by FDA, with a PDUFA date of Oct 26, 2026; this raises the potential upside from partner royalties and milestone payments. Read More.
• Neutral Sentiment: Analyst coverage and metric breakdowns — coverage from Zacks and others highlights the beats and details how key metrics compare to estimates and prior-year figures, useful for modeling but not a new catalyst by itself. Read More.
• Negative Sentiment: Profitability and valuation remain concerns — despite the quarter’s beat, Ionis remains loss-making with a negative net margin and negative ROE; consensus still models a full-year negative EPS, and longer-term profitability/earnings visibility could limit multiple expansion. Read More.

Wall Street Analysts Forecast Growth

IONS has been the subject of a number of research reports. Wall Street Zen downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Stifel Nicolaus boosted their price target on shares of Ionis Pharmaceuticals from $73.00 to $77.00 and gave the company a “hold” rating in a report on Thursday, February 26th. TD Cowen reduced their price target on shares of Ionis Pharmaceuticals from $110.00 to $108.00 and set a “buy” rating for the company in a report on Thursday, April 23rd. HC Wainwright boosted their price target on shares of Ionis Pharmaceuticals from $110.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $97.35.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.